Biocompatible self-illuminating sphingomyelin nanosystems for photodynamic-based cancer therapy

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2025-06-29 DOI:10.1016/j.jconrel.2025.113982

M. Abal-Sanisidro , A. Palencia-Campos , L. Ruiz-Cañas , J. García-Fernández , L. Cañada-García , S. Batres-Ramos , R. López-López , R. Moreno , M. Martín-Pastor , B. Sainz Jr , M. de la Fuente

{"title":"Biocompatible self-illuminating sphingomyelin nanosystems for photodynamic-based cancer therapy","authors":"M. Abal-Sanisidro , A. Palencia-Campos , L. Ruiz-Cañas , J. García-Fernández , L. Cañada-García , S. Batres-Ramos , R. López-López , R. Moreno , M. Martín-Pastor , B. Sainz Jr , M. de la Fuente","doi":"10.1016/j.jconrel.2025.113982","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, personalized medicine has emerged as a key approach to potentially treat numerous diseases, in particular cancer. Within this field, nanotechnology has arisen as a promising tool with multiple biomedical applications, and organic nanoparticles stand out due to their improved translational prospects, primarily attributed to their biocompatibility and biodegradability. In this context, sphingomyelin nanoemulsions (SNs) are promising carriers for the delivery of innovative therapeutics and the advancement of novel anticancer therapeutics. Herein, we aimed to develop a new and novel type of biocompatible and biodegradable self-illuminating (SI) nanosystems for the treatment of pancreatic cancer by photodynamic therapy (PDT), upon association of the bioluminescent protein RLuc8 to SNs, and encapsulation of the photosensitizer Rose Bengal (SI-SNs). We present here a deep characterization of the developed SI-SNs and a first <em>in vitro</em> and <em>in vivo</em> proof of concept, highlighting the potential of this strategy for the development of innovative nanotherapeutics for pancreatic cancer.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113982"},"PeriodicalIF":10.5000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925006030","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, personalized medicine has emerged as a key approach to potentially treat numerous diseases, in particular cancer. Within this field, nanotechnology has arisen as a promising tool with multiple biomedical applications, and organic nanoparticles stand out due to their improved translational prospects, primarily attributed to their biocompatibility and biodegradability. In this context, sphingomyelin nanoemulsions (SNs) are promising carriers for the delivery of innovative therapeutics and the advancement of novel anticancer therapeutics. Herein, we aimed to develop a new and novel type of biocompatible and biodegradable self-illuminating (SI) nanosystems for the treatment of pancreatic cancer by photodynamic therapy (PDT), upon association of the bioluminescent protein RLuc8 to SNs, and encapsulation of the photosensitizer Rose Bengal (SI-SNs). We present here a deep characterization of the developed SI-SNs and a first in vitro and in vivo proof of concept, highlighting the potential of this strategy for the development of innovative nanotherapeutics for pancreatic cancer.

Abstract Image

查看原文本刊更多论文

生物相容性和多功能自发光鞘磷脂纳米系统作为光动力学癌症治疗的有效多功能工具

近年来，个性化医疗已经成为潜在治疗多种疾病的关键方法，尤其是癌症。在这一领域，纳米技术已经成为一种具有多种生物医学应用前景的工具，有机纳米颗粒因其生物相容性和生物可降解性而具有更好的转化前景而脱颖而出。在这种情况下，鞘磷脂纳米乳（SNs）是一种很有前途的载体，用于递送创新疗法和推进新型抗癌疗法。在此，我们旨在开发一种新型的生物相容性和可生物降解的自发光（SI）纳米系统，通过光动力疗法（PDT）治疗胰腺癌，将生物发光蛋白RLuc8与SNs结合，并包封光敏剂Rose Bengal （SI-SNs）。在此，我们对开发的SI-SNs进行了深入的表征，并首次在体外和体内验证了这一概念，强调了该策略在胰腺癌创新纳米疗法开发中的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.